Skip to main content
Sign In
 

Clinical Trials

Volunteer to Be Part of a Research Study


Page through all School of Medicine clinical and research trials below. There are two categories: 

  • Detailed Trial Descriptions, submitted by researchers, includes trial specifics and contact information.

  • Additional Clinical Trials, which include basic study details. To contact the researcher either Google the PI (primary investigator) name or use our campus directory.

If you are a researcher seeking volunteers and your study is not posted, please submit your Web ad here.  

Detailed Trial Descriptions

 Results From Research and Clinical Trials : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 4, items 1 to 30 of 113.
COMIRB Approved Advertisement TitleStudy GoalsEligibility CriteriaDate Posted
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 4, items 1 to 30 of 113.
Do you have Parkinson's Disease?
To explore the effects of different doses of endurance exercise in people with PD.​
Persons 40-80 who have been diagnosed with Parkinson's Disease and are not yet taking medication or plant to start medication within the next 6 months. You must be willing to begin the exercise program immediately or after a delay of 6 months and willing to do aerobic exercise on a treadmill.
10/31/2014
Do you have Atopic Dermatitis (Eczema)?
To study eczema
Males and Females between 3 and 80 who have atopic dermatitis or males and females between 8 months and 80 who have a history of, or an active case of eczema hereticum (wide-spread herpes skin infection along with atopic dermatitis.
10/31/2014
Better Control of Type 2 Diabetes May Decrease Your Risk for Cardiovascular Disease.
To look at the use of an extended release formula of Exenatide compared to a placebo to maintain normal glucose levels. Ultimately to see better control of diabetes and a decrease in cardiovascular disease events.​
Person 18+ with Type 2 Diabetes and take no more than 2 diabetes medications with stale doses for the last 3 months. Must not have a planned or anticipated revascularization procedure, but may have a history of cardiovascular disease and must see your primary care physician at least twice a year.
10/31/2014
Are you a Non-smoking Adult between the ages of 45 and 85?
We are interested in learning more about smoking related lung disease, and need healthy non-smoking participants.
45-85 years old Non-Hispanic White or African American No smoking history No evidence of lung disease
10/31/2014
Influenza Study
Doctors at the National Institutes of Health are conducting a research study (IRC-004) to investigate whether treating the flu decreases the amount of virus we can detect in your nose, and to understand whether the change in the amount of virus is associated with changes in your symptoms.
Volunteers may be male or female and must: -be at least 18 years old -have a history of an influenza-like illness -have an onset of illness within the past 48 hours -test positive for influenza
10/31/2014
Alterations in Lung Microbiome in Acute and Chronic HIV Infection
This is a prospective, observational cohort study. Three groups (A1, A2, and B) will be enrolled in parallel.
-Men and women >/= 18 years. -Willing to follow all research requirements -Willing to provide written informed consent -Group A1- acute HIV infection defined as a high risk HIV exposure within the prior 30 days, or recent HIV-1 seroconversion defined as those with a high risk HIV-1 exposure -Group A2- healthy controls: HIV-1 seronegative with no high risk HIV-1 exposure in the prior 30 days and no chronic medical illness -Group B- HIV-1 infection diagnosed by a previous positive antibody or PCR test have been recommended to initiate HAART by their health care provider You should not be in this study if you are a pregnant or planning to become pregnant.
10/31/2014
Has your child been diagnosed with generalized anxiety disorder?
to study sleep and brain activity
• between the ages of 12 & 18 • diagnosed with GAD OR • not diagnosed with any psychological disorders AND who are • right-handed • without orthodontic braces • not taking sleep medications
10/31/2014
Volunteers needed to Participate in a Research Study about Rheumatoid Arthritis
The purpose of this study is to learn more about how rheumatoid arthritis develops by studying people who do not have rheumatoid arthritis. Your participation in this study will help us determine if certain genetic and environmental factors affect the chances of developing RA-related autoantibodies in absence of rheumatoid arthritis.
You may be eligible to participate in the study if: -You are at least 18 years old -You do NOT have Rheumatoid Arthritis (RA)
10/31/2014
Restoring Insulin Secretion (RISE)
The Children’s Hospital Colorado Clinical Translational Research Center and the National Institutes of Health are conducting a study. This study is aimed at testing whether early treatment is beneficial to kids with early type 2 diabetes and kids at high risk of diabetes.
10-19 years of age, Pubertal, Overweight, Fasting glucose: >90 mg/dl; Impaired glucose tolerance: >140 mg/dl; Pre-diabetes or diagnosed with diabetes for less than 6 months; Metformin
10/31/2014
Participate in a Research Study at the University of Colorado. UC Denver is Conducting a Study on Back Pain and Spinal Manipulation at the Anschutz Medical Campus
To study muscle activity during chiropractic spinal manipulations
1) 18-55 years of age 2) Male 3) Must have low back pain
10/31/2014
Have you experienced a preterm birth?
If you participate, the information we learn from you will help us better understand how and why 1 out of 10 pregnancies in the US end in preterm birth.
1. Women ages 18-45 years old 2. willing to meet for 1-2 hours in a focus group setting 3. a mother of a baby who was born more than 3 weeks before your due date
10/31/2014
Do You Smoke?
To figure out how these lung substances work in people who drink too much alcohol, who usually smoke, compared to those who do not drink heavily, but who smoke.
Smoking and nonsmoking males
10/31/2014
Parents or Legal Guardians of Children with Disabilities
Assistive Technology Partners, University of Colorado, Anschutz Medical Campus, is performing a study investigating the impact Socially Assistive Robotics has on motor, communication and cognitive skills of children with disabilities.
Children between the ages of 18 months to 5 years of age Have Significant motor and communication disabilities/delays NOT been diagnosed with blindness or deafness They are without a seizure disorder or with a well-controlled seizure disorder They have been on stable medication regime for the past 12 weeks, if they are currently taking medication.
10/31/2014
The Influence of Couples' Conversation on the Heart
The purpose of the study is to examine the influence that conversations between married couples have on the functioning of the heart.
Married Christian couples who: • Have been married for at least 1 yr. • Both believe in prayer. • Are not currently taking heart medications. • Do not have heart problems. • Are not pregnant.
10/31/2014
Help Us Learn About Schizophrenia!
Help us learn more about a new drug that may improve thinking and concentration in people with schizophrenia.
We are looking for: Male and female adults who smoke 18-50 years old No previous or current mental illness No drug use Willing to use nicotine patch during study hospital visit If female, willing to use birth control during the study
10/31/2014
Participants with Chronic Kidney Disease and Vitamin D Deficiency Needed for a Research Study
This study will examine whether nutritional or active vitamin D supplementation will improve blood vessel function​.
Person 18-80 with chronic kidney disease stage 3B or 4 (estimated GFR 44-15 m;/min) with a vitamin D deficiency or insufficiency.  Women must not be pregnant or breastfeeding.
10/30/2014
Trouble Sleeping?
Study the effects of two different study drugs, one or two non-drug interventions and/or a combination of both to treat insomnia.
Persons 21+ who have trouble falling or staying asleep at night.
10/30/2014
Give Us a Hand
To better understand Multiple Sclerosis in children and teens.
Between the ages of 3-20 AND have Multiple Sclerosis diagnosed before 18 OR Do not have MS
10/30/2014
Are you an African American with asthma?
 We are studying why some African American people have trouble with their asthma despite taking asthma medications.
 Children age 5-17 and non-smoking Adults age18 and older who have asthma symptoms despite asthma treatment • African American ancestry (have at least one    African American grandparent)
10/30/2014
Peanut and Tree-Nut Allergy Research Study
The purpose of this study is to determine how the body's immune system interacts with nuts and other foods to cause allergic reaction.
6-75 years of age. Have a diagnosis of peanut and/or tree-nut allergy made by either skin test or blood tests. Have no known peanut and/or tree-nut allergy.
10/30/2014
Research about the Effect of Carbamazepine medication on the Etonogestrel Contraceptive Implant (Implanon®/Nexplanon®)
Do you currently have a birth control implant (Implanon®/ Nexplanon®) and are interested in participating in a research study to better understand the effects of certain medication on the implant?
• Women ages 18-45 who have had a birth control implant 1 to 3 years • Do not take any medications that are known to effect liver enzymes • Be willing to abstain during the study period or use a secondary form of non-hormonal contraception • Have a body mass index between 15 and 30 • Have baseline systolic blood pressure
10/30/2014
Do you have human growth hormone (hGH) deficiency?
Primary: To demonstrate a clinical superiority of MOD-4023 over placebo in terms of decrease in Fat Mass (FM) in adult subjects with Growth Hormone Deficiency Secondary a. To determine the efficacy of MOD-4023 over placebo in other body composition variables (such as lean body mass and waist-to-hip ratio) b. To evaluate the safety and tolerability of MOD-4023 over placebo in adult subjects with GHD c. To determine the IGF-I and IGFBP-3 serum levels
Adult men and women aged 23 to 70 years of age diagnosed with either adult or childhood onset growth hormone deficiency (GHD).
10/30/2014
Are you a parent of a child with a developmental disability and willing to contribute to a research project to increase awareness and understanding?
The purpose of this study is to gain knowledge on the topic of everyday stressors that affect the lives of children with developmental disabilities, as well as their parents/caregivers
Are you a parent of a child with a developmental disability and willing to contribute to a research project to increase awareness and understanding?
10/30/2014
Healthy Female Adults Needed!!!
For brain imaging research study on how the brain works with we taste sweets. Your participation could help us to develop treatments and preventive measures for anorexia nervosa and obesity
Healthy females 22 to 29 who are right-handed, free of medication with no serious medical conditions, permanent metal implants or braces/retainers, and are at a healthy body weight.
10/30/2014
Healthy Volunteers Needed for a Research Study on Kidney Disease
To understand whether patients with kidney disease with or without a kidney transplant have high levels of microparticles compared to healthy adults. Microparticles are small vesicles that our cells release in response to injury.
Healthy individuals 18 and older. *If you have diabetes, high blood pressure, or heart disease you will not qualify for the study. Pregnant and lactating women are not eligible.
10/30/2014
Investigations in Gestational Origins of Lifetime Development: Understanding health begins before birth. Are you in your first trimester of Pregnancy?
To learn more about how your metabolism is connected to your baby's growth and development
Healthy Women ages 18-35 who are 10-14 weeks pregnant with single baby.  Norm BMI or 30-38 who are willing to complete 5 visits during pregnancy and agreeable to an infant blood draw at birth and DXA postpartum.  Delivery must be at University of Colorado Hospital.  there is an option to take part in a 1 year follow-up which entails an additional 4 visits and another DXA at 1 year of life.
10/29/2014
We are Currently Enrolling People with Down syndrome for a study in Dr. Pelak's Brain and Vision Research lab at the University of Colorado Anschutz Medical Campus.
To examine visual brain function in people with mild memory impairments to detect early signs of Alzheimer's Disease.​
Persons 19-30 who have Down Syndrome
10/29/2014
You are invited to participate in EMERALD, as research study about Metformin and Type 1 Diabetes in Adolescents
​To determine the effects of Metformin on Cardiovascular Function in Adolescents with Type 1 Diabetes.
Persons 12-21 who have Type 1 Diabetes, non-smoker and exercise no more than 3 hours a week.  You must be willing to take metformin or placebo (sugar pill) for 3 months.   Other exclusions apply, please contract study for more information
10/29/2014
Children's Hospital, department of Pediatric Neurology is conducting a research study
Evaluating the effects of a single treatment of injected BOTOX® (Botulinum Toxin Type A) for chronic migraine(s) in adolescents.
Adolescents 12-17 who have no serious medical conditions but have at least 15 headaches a month for the last 6 months. You not have any previous BOTX treatments or are not currently using any prophylactic medicine.
10/29/2014
Non-Alcoholic Fatty Liver Disease and Obstructive Sleep Apnea: Mechanistic Links between Hypoxemia and Liver Injury
To learn if obstructive sleep apnea and low oxygen levels have a role in developing Non-Alcoholic Fatty Liver Disease (NAFLD).​​​
Children 10-17 who have a normal weight and no serious medical problems
10/29/2014

​Additional Clinical Trails

 Results From Research : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 16, items 1 to 30 of 461.
Protocol TitlePI NameInstitution Number
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 16, items 1 to 30 of 461.
Eisenmenger Quality Enhancement Research Initiative (QuERI). Sponsor Protocol 20111728. WIRB Protocol No. 20111728
Kay, Joseph12-0926
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Two Doses of Subcutaneous Pulsatile GnRH Administered via OmniPod Pump for Ovulation Induction in Female Subjects with Primary Amenorrhea with Hypogonadotropic Hypogonadism. Sponsor Protocol No. 000070. WIRB Protocol No. 20140452
Santoro, Nanette13-2352
A Phase 1b, multi-center, two parallel group, open-label, drug-drug interaction study to assess the effect of LDE225 on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumors. Sponsor Protocol No. CLDE225A2112. WIRB Protocol No.20130681
Lewis, Karl13-2556
A Randomized Phase 2 Study of Oral AP26113 in Patients with ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Been Treated with Crizotinib. Sponsor Protocol No. AP26113-13-201. WIRB Protocol No.20131562
Camidge, David13-2648
A MULTI-CENTER,OPEN LABEL, FIRST IN HUMAN, PHASE I DOSE ESCALATION STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO6839921, AN MDM2 ANTAGONIST FOLLOWING INTRAVENOUS ADMINISTRATION IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ACUTE MYELOID LEUKEMIA (AML). Sponsor Protocol No. NP28903. WIRB Protocol No. 20140542
Gore, Lia13-2649
A 12-Week Multicenter, Randomized, Double-Blind,Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis with a Long-Term Extension Period. Sponsor Protocol No. I1F-MC-RHBC(b). WIRB Protocol No. 20121432
Armstrong, April13-2723
A PHASE II, RANDOMIZED STUDY OF MPDL3280A ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA. Sponsor Protocol No. WO29074. WIRB Protocol No. 20131502
Lam, Elaine13-2806
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estrogen or Progesterone Receptor-Positive and HER2-Normal. Sponsor Protocol No. MDV3100-12. WIRB Protocol No. 20131280
Elias, Anthony13-2892
A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM). Sponsor Protocol No. 109MS401. WIRB Protocol No. 20140071
Schreiner, Teri13-2897
A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination with VTX-2337 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Sponsor Protocol No. VRXP-A202. WIRB Protocol No. 20131627
Jimeno, Antonio13-2911
A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Associated with Liver Disease Prior to an Elective Procedure. Sponsor Protocol No. E5501-G000-311. WIRB Protocol No. 20131907
Everson, Greg13-2914
A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcinerurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation- Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM). Sponsor Protocol No. CRAD001A2433. WIRB Protocol No. 20140590
Wiseman, Alexander13-2918
PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer. Sponsor Protocol No. MDV3100-14. WIRB Protocol No. 20131112
Crawford, E13-2937
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy. Sponsor Protocol No. D0816C00002. WIRB Protocol No. 20131789
Davidson, Susan13-2969
A Phase 1b, open-label study to assess the safety and tolerability of ONT-380 combined with capecitabine and trastuzumab, alone and in combination in HER2+ metastatic breast cancer. Sponsor Protocol No. ONT-380-005. WIRB Protocol No. 20140127
Borges, Virginia13-3000
A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination with Abiraterone in Chemotherapy Naïve Subjects with Bone-Metastatic Castration-Resistant Prostate Cancer. Sponsor Protocol No. XL184-210. WIRB Protocol No. 20140076
Flaig, Thomas13-3004
A Phase II, Multicenter, Randomized, Observer-Blind, Controlled Study to Evaluate Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women. Sponsor Protocol No. V98_12. WIRB Protocol No. 20140324
Gibbs, Ronald13-3019
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of NNZ-2566 in Fragile X Syndrome. Sponsor Protocol No. Neu-2566-FXS-001. WIRB Protocol No. 20132053
Tartaglia, Nicole13-3117
Evaluation of Acute Rejection Rates in de novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (belatacept) -based Immunosuppression. Sponsor Protocol No, IM103177. WIRB Protocol No. 20132295
Wiseman, Alexander13-3123
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected with Human Immunodeficiency Virus (HIV). Sponsor Protocol No. AI444216. WIRB Protocol No. 20140021
Campbell, Thomas13-3250
A Multi-Center, Multi-National Clinical Study to Evaluate the Safety and Effectiveness of the Essure® (Model ESS505) Device to Prevent Pregnancy in Women Who Are Seeking Permanent Contraception. Sponsor Protocol No. 16973. WIRB Protocol No. 20140151
Tocce, Kristina13-3258
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF 3-MONTH SUBCUTANEOUS REGN1033 TREATMENT IN PATIENTS WITH SARCOPENIA. Sponsor Protocol No. R1033-SRC-1239. WIRB Protocol No.20131518
Schwartz, Robert13-3265
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Solid Tumors, Including Glioma, with an IDH1 Mutation Sponsor Protocol No. AG120-C-002 WIRB Protocol No. 20140544
Gore, Lia14-0012
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation. Sponsor Protocol No. AG120-C-001. WIRB Protocol No. 20140421
Pollyea, Daniel14-0013
A Phase Ib dose escalation/randomized phase II multicenter, open-label study of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. Sponsor Protocol No. CBYL719X2104. WIRB Protocol No.20140692
Jimeno, Antonio14-0034
A safety study for MSB0010445 in combination with Stereotactic Body Radiation in advanced melanoma subjects following prior treatment with ipilimumab Sponsor Protocol No. EMR 062235-005 WIRB Protocol No. 20140683
Lewis, Karl14-0050
Phase 1 study of ONT-10, a liposomal MUC1 cancer vaccine, in patients with solid tumors. Sponsor Protocol No. ONT-10-001. WIRB Protocol No. 20140202
Borges, Virginia14-0063
Maintenance therapy with ONT-10, a liposomal MUC1 cancer vaccine, in patients who have previously received ONT-10. Sponsor Protocol No. ONT-10-002. WIRB Protocol No. 20140221
Borges, Virginia14-0064
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination with Paclitaxel in Patients with Locally Recurrent or Metastatic Breast Cancer. Sponsor Protocol No. 18R5-002. WIRB Protocol No. 20140743
Diamond, Jennifer14-0065
International, multicenter, open-label, treatment-extension study for subjects who completed a Phase 1 or Phase 2 parental study to continue receiving treatment with SAR245408 or SAR245409 as a monotherapy or as a combination regimen. Sponsor Protocol No. TED12414. WIRB Protocol No. 20120931
Gore, Lia14-0079